{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-018297","form_type":"8-K","ticker":"MNKD","cik":"0000899460","company_name":"MANNKIND CORP","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.242825+00:00","generated_at":"2026-06-26T00:13:48.177912+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MannKind Q1: Afrezza net revenue $9.8M (+21% YoY); net loss $26.0M; cash $233M","bullets":["Afrezza net revenue $9.8M, up 21% vs Q1 2021; gross margin improved to 77% from 47%.","Net loss $26.0M ($0.10 per share) vs $12.9M ($0.05) in Q1 2021, driven by lower collaboration revenue.","Cash and investments $233.0M at March 31, 2022; Tyvaso DPI PDUFA action date expected May 2022.","Collaborations & services revenue $2.2M, down $7.2M due to completion of R&D services for United Therapeutics.","Deferred revenue from commercial supply agreement with United Therapeutics increased to $25.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-018297","json":"https://secwatch.observer/filing/0001564590-22-018297.json","markdown":"https://secwatch.observer/filing/0001564590-22-018297.md","text":"https://secwatch.observer/filing/0001564590-22-018297.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899460/000156459022018297/0001564590-22-018297-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899460/000156459022018297/mnkd-8k_20220505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T00:13:48.177912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}